Management of Severe Hypertriglyceridemia

Immediate Intervention

The American College of Cardiology recommends initiating fenofibrate 54-160 mg daily immediately as first-line therapy to reduce the risk of acute pancreatitis in patients with severe hypertriglyceridemia, defined as triglycerides between 500-999 mg/dL, which places them at significant risk of pancreatitis 1, 2, 3
Fenofibrate will reduce triglycerides by 30-50%, bringing levels below the critical 500 mg/dL threshold where pancreatitis risk escalates dramatically, with a 14% incidence of pancreatitis in patients with severe hypertriglyceridemia making immediate fibrate therapy the standard of care 1, 2

The American College of Cardiology suggests implementing aggressive dietary fat restriction to 20-25% of total daily calories and completely eliminating all added sugars and alcohol to reduce triglyceride levels 1, 2, 3
Restricting added sugars to <5% of total daily calories, essentially elimination, can reduce hepatic triglyceride production, and complete alcohol abstinence is mandatory at this triglyceride level as alcohol synergistically worsens hypertriglyceridemia and can precipitate hypertriglyceridemic pancreatitis 2, 3, 1, 4

The American College of Cardiology recommends screening for uncontrolled diabetes, hypothyroidism, renal disease, and medications that elevate triglycerides, as poor glycemic control is often the primary driver of severe hypertriglyceridemia and optimizing diabetes management can dramatically reduce triglycerides independent of lipid medications 1, 2, 3, 4
If diabetes is present with poor control, treating hyperglycemia first before adding additional lipid medications may be more effective than pharmacotherapy, and discontinuing or substituting medications that raise triglycerides if clinically feasible is also recommended 1, 2

The American College of Cardiology advises against starting statin therapy immediately, instead waiting until triglycerides fall below 500 mg/dL with fenofibrate therapy, then reassessing LDL-C and initiating statin if indicated, as starting with statin monotherapy when triglycerides are ≥500 mg/dL is inappropriate and provides only 10-30% triglyceride reduction 1, 2, 3
Once triglycerides are reduced below 500 mg/dL, obtaining a fasting lipid panel to calculate actual LDL-C and initiating moderate-intensity statin therapy if LDL-C remains elevated or cardiovascular risk is high is recommended 2, 3

The American College of Cardiology suggests that if combining fenofibrate with a statin in the future, using lower statin doses and monitoring for myopathy with baseline and follow-up creatine kinase levels is necessary, as fenofibrate has a better safety profile than gemfibrozil when combined with statins but myopathy risk still exists 2, 3

The American College of Cardiology recommends considering prescription omega-3 fatty acids, such as icosapent ethyl 2-4 g/day, if triglycerides remain >200 mg/dL after 3 months of fenofibrate, lifestyle optimization, and statin therapy, as icosapent ethyl is indicated for patients with triglycerides ≥150 mg/dL on maximally tolerated statin with established cardiovascular disease or diabetes with ≥2 additional risk factors 1, 2, 3
The REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events with icosapent ethyl, and monitoring for increased risk of atrial fibrillation with prescription omega-3 fatty acids is necessary 2, 3

The American College of Cardiology suggests reassessing fasting lipid panel in 4-8 weeks after initiating fenofibrate to evaluate triglyceride response and determine need for additional interventions, targeting triglycerides <500 mg/dL initially to reduce pancreatitis risk, then aiming for <200 mg/dL to reduce cardiovascular risk 1, 2, 3
Targeting non-HDL-C <130 mg/dL, monitoring liver enzymes, and following up every 6-12 months with fasting lipid panels is also recommended 1, 2, 4